Searched for
BIOCON API BUSINESS
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon drops plan to launch weight-loss drugs in China, executive saysBiocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense local competition...
- Biocon Q4 Results: Net profit drops 57% to Rs 136 croreTotal revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, representing an EBITDA margin of 24% ...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- Biocon weighs sale of $1.5 billion generic API businessThe Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for ...
- Biocon Q2 Results: Profit zooms 168% YoY to Rs 126 crore; revenue jumps 49%EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. ...
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily ...
- Viatris puts India API business on the blockHowever, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...
- Kotak fund invests Rs 1070 crore in BioconEshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...
- Biocon's growth drivers are in place: 5 reasons it is this week's stock pickImproving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...
- Biocon plunges 5% even as Q1 profit rises 71%Siddharth Mittal, CEO & Managing Director, Biocon, said, “The strong year-on-year growth of the segment was driven by both our API and Form...
- Hold Biocon, target price Rs 380: ICICI DirectBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 44314.15 crore) operating in Pharmaceuticals secto...
- Biocon acquires Vishakapatnam-based company's manufacturing plantBiotechnology major Biocon today said it has acquired a manufacturing unit of Vishakapatnam- based Acacia Lifesciences for an undisclosed a...
- Biocon to invest 10% of biopharma revenues on R&D next fiscalThe Bengaluru-based company has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the correspo...
- Biocon completes divestment of its enzyme businessBiotechnology firm, Biocon on Monday said it has completed all activities related to the divestment of enzymes business to Novozymes South ...
Load More
